Fluoguide: Continued progress - SEB

FluoGuide has been demonstrating good progress with its clinical and preclinical programs, and FG001 appears to be exceeding expectations, with higher optimal dosing than the company projected. Although in principle, this is positive because it means a better product, it also means more testing of doses, and hence delays to the start of part 2 of the trial. We have adjusted our model accordingly.

Länk till analysen i sin helhet: https://research.sebgroup.com/corporate/reports/110235